Cargando…
Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery w...
Autores principales: | Zhan, Yixiang, Ni, Kemin, Liu, Zhaoce, xin, Ran, Han, Qiurong, Ping, Hangyu, Liu, Yaohong, Zhao, Xuanzhu, Wang, Wanting, Yan, Suying, Sun, Jing, Zhang, Qinghuai, Wang, Guihua, Zhang, Zili, Zhang, Xipeng, Hu, Xia, Li, Guoxun, Zhang, Chunze |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238399/ https://www.ncbi.nlm.nih.gov/pubmed/37268749 http://dx.doi.org/10.1038/s41598-023-33153-8 |
Ejemplares similares
-
Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
por: Zhang, Chunze, et al.
Publicado: (2022) -
Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone
por: Ni, Kemin, et al.
Publicado: (2023) -
The stool syndecan2 methylation test is more robust than blood tests for methylated septin9, CEA, CA19-9 and CA724: a diagnostic test for the early detection of colorectal neoplasms
por: Zhan, Yixiang, et al.
Publicado: (2023) -
Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
por: Yuan, Zhen, et al.
Publicado: (2022) -
Young Patients With Colorectal Cancer Have Higher Early Mortality but Better Long-Term Survival
por: Wang, Shuyuan, et al.
Publicado: (2022)